Skip to main content
. 2018 Aug 14;9:1905. doi: 10.3389/fimmu.2018.01905

Figure 2.

Figure 2

Oral administration of Lactobacillus sakei WIKIM30 ameliorates atopic dermatitis (AD)-like symptoms. (A) Experimental design. To induce AD-like immunologic features and skin lesions in mice, DNCB was applied to the dorsal skin. Phosphate-buffered saline (PBS), ketotifen, or L. sakei WIKIM30 was orally administered once daily for 6 weeks. (B) AD-like skin lesions were evaluated by visual observation. (C,D) Serum immunoglobulin (Ig)E and interleukin (IL)-4 levels were detected by sandwich enzyme-linked immunosorbent assay. (E,F) Dorsal skin sections were stained with hematoxylin and eosin or Toluidine Blue. Skin thickness and cell infiltration (E) and mast cell number and degranulation (F) were evaluated by histological analysis. Data represent the mean ± SE of n = 5 mice per group in three independent experiments. Student’s t-test (unpaired); *p < 0.05, **p < 0.01 vs. AD group.